
1-year outcomes of REVISE-Diabesity clinical trial

Randomisation to Endobarrier alone Versus with Incretin analogue in Sustained Diabesity



Dr Bob Ryder, Birmingham City Dr Barbara McGowan, Guys, London Dr Piya Sen Gupta, Kings, London and Birmingham City Dr Russell Drummond, Glasgow Royal Prof Stephanie Amiel, Kings, London



ABCD Meeting, Manchester, Spring 2016



Introduction – Bob Ryder

- Prologue
- Concept
- Aims
- Methods

Prologue

Diabetologia DOI 10.1007/s00125-011-2204-7

ARTICLE

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol

E. L. Lim • K. G. Hollingsworth • B. S. Aribisala • M. J. Chen • J. C. Mathers • R. Taylor

Received: 22 March 2011 / Accepted: 5 May 2011 ① The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract

Aims/hypothesis Type 2 diabetes is regarded as inevitably progressive, with irreversible beta cell failure. The hypothesis was tested that both beta cell failure and insulin resistance can be reversed by dietary restriction of energy intake.

Methods Eleven people with type 2 diabetes (49.5± 2.5 years, BMI 33.6±1.2 kg/m², nine male and two female) were studied before and after 1, 4 and 8 weeks of a 2.5 MJ (600 kcal)/day diet. Basal hepatic glucose output, hepatic and peripheral insulin sensitivity and beta cell function were measured. Pancreas and liver triacylglycerol content was measured using three-point Dixon magnetic resonance imaging. An age-, sex- and weight-matched group of eight non-diabetic participants was studied.

Results After 1 week of restricted energy intake, fasting plasma glucose normalised in the diabetic group (from $9.2\pm$ 0.4 to 5.9 ± 0.4 mmol/l; p=0.003). Insulin suppression of hepatic glucose output improved from $43\pm4\%$ to $74\pm5\%$ (p=0.003 vs baseline; controls $68\pm5\%$). Hepatic triacylglycerol content fell from $12.8\pm2.4\%$ in the diabetic group to $2.9\pm$ 0.2% by week 8 (p=0.003). The first-phase insulin response increased during the study period (0.19 ± 0.02 to $0.46\pm$ 0.07 nmol min⁻¹ m⁻²; p=0.001) and approached control

E. L. Lim⁺K. G. Hollingsworth⁺B. S. Aribisala⁺M. J. Chen⁺ R. Taylor (^[C]) Magnetic Resonance Centre, Institute of Cellular Medicine, values (0.62±0.15 nmol min⁻¹ m⁻²; p=0.42). Maximal insulin response became supranormal at 8 weeks (1.37± 0.27 vs controls 1.15±0.18 nmol min⁻¹ m⁻²). Panereatic triacylglycerol decreased from 8.0±1.6% to 6.2±1.1% (p=0.03).

Conclusions/interpretation Normalisation of both beta cell function and hepatic insulin sensitivity in type 2 diabetes was achieved by dietary energy restriction alone. This was associated with decreased pancreatic and liver triacylglycerol stores. The abnormalities underlying type 2 diabetes are reversible by reducing dietary energy intake.

Keywords Insulin secretion Liver fat Low energy diet -Pancreatic fat Type 2 diabetes

Abbreviation

ffm Fat-free mass

Introduction

Type 2 diabetes has long been regarded as a chronic progressive condition, capable of amelioration but not cure. A steady rise in plasma glucose occurs irrespective of the degree of control or type of treatment [1]. Beta cell function declines linearly with time, and after 10 years more than 50% of individuals require insulin therapy [2]. The underlying changes in beta cell function have been well described [2].




Ee Lim



Roy Taylor

11 patients diabetes <4years duration 600 kcal diet/day diet for 8 weeks:



Lim EL, et al Diabetologia 2011; 54: 2506-2514

11 patients diabetes <4years duration 600 kcal diet/day diet for 8 weeks:

- Decreased liver fat
- Decreased pancreatic fat
- Normalisation of beta cell function
- Normalisation hepatic insulin sensitivity
- Normalisation glucose metabolism
 - ie "Cure" of type 2 diabetes!

11 patients diabetes <4years duration 600 kcal diet/day diet for 8 weeks:

- Decreased liver fat
- Decreased pancreatic fat
- ?Decreased coronary artery fat
- ?Decreased carotid artery fat

Emerging Treatments and Technologies ORIGINAL ARTICLE

The Treat-to-Target Trial

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MATTHEW C. RIDDLE, MD JULIO ROSENSTOCK, MD OHN GERICH, MD

ON BEHALF OF THE INSULIN GLABOINE 4002 STUDY INVESTIGATORS*

OBJECTIVE - To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA110

RESEARCH DESIGN AND METHODS - In a randomized, open-label, parallel, 24week multicenter trial, 756 overweight men and women with inadeouate glycemic control (HbA: >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG) ≤100 mg/dl (5.5 mmol/l). Outcome measures were FPG, HbA1e, hypoglycemia, and percentage of patients reaching HbA1c ≤7% without documented nocturnal hypoglycemia.

RESULTS - Mean FPG at end point was similar with glargine and NPH (117 vs. 120 mg/dl [6.5 vs. 6.7 mmol/l]), as was HbA1c (6.96 vs. 6.97%). A majority of patients (~60%) attained $\rm HbA_{1c} \leq 7\,\%$ with each insulin type. However, nearly 25% more patients attained this without documented nocturnal hypoglycemia (\leq 72 mg/dl [4.0 mmol/l]) with glargine (33.2 vs. 26.7%, P < 0.05). Moreover, rates of other categories of symptomatic hypoglycemia were 21–48% lower with glargine

CONCLUSIONS - Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7% HbA1c in a majority of overweight patients with type 2 diabetes with HbA1c between 7.5 and 10.0% on oral agents alone. In doing this, glargine causes significantly less nocturnal hypoglycemia than NPH, thus reducing a leading barrier to initiating insulin. This simple regimen may facilitate earlier and effective insulin use in routine medical practice, improving achievement of recommended standards of diabetes care

Diabetes Care 26:3080-3086, 2003

order of B-cell dysfunction. Patients using oral therapy for it seldom achieve and maintain the recommended 7% HbA1c goal (1,2) for glycemic control and are exposed to increasing risks of diabetic complications as control worsens over time (3-5). The U.K. Prospective Diabetes Study (UKPDS) (6) showed that intensive treatment can reduce these clinical risks, and a recently reported substudy of the UKPDS (7) confirmed that early addition of insulin to oral therapy can safely keep HbA1, close to 7% in the first 6 years after diagnosis. However, the majority of patients

ype 2 diabetes is a progressive dis-

with a longer duration of diabetes remain poorly controlled with oral agents, and use of insulin, which could improve glycemic control, is often long delayed and not aggressive enough. The reluctance to initiate insulin therapy seems partly due to its perceived complexity, the belief that insulin is not effective for type 2 diabetes (8), and fear of hypoglycemia, which may be the greatest barrier (9).

A regimen that may make initiation of insulin simpler and more effective has been tested in several small studies (10-

of longile prior nsulin is defined



Matthew Riddle Julio Rosenstock Riddle et al, Diabetes Care 2003; 26: 3080-3086

Diabenologia (2008) 49: 442-451 DOI:10.1007/s00125.005.0132.0

ARTICLE

H. Yki-Järvinen · R. Kauppinen-Mäkelin · M. Tiikkainen · M. Vähätalo · H. Virtamo · K. Nikkilä · T. Tulokas - S. Hulme - K. Hardy - S. McNulty J. Hänninen · H. Levänen · S. Lahdenperä · R. Lehtonen - L. Ryysy

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

Received: 4 May 2005 / Accepted: 7 November 2005 / Published online: 3 February 2006 C Springer-Verlag 2006

symptomatic hypoglycaemia. Methods: In this investigator-initiated open, parallel-group clinical trial involving with poor glycaemic control (HbA1, ≥8.0%) on oral hypoglycaemic agents (90% using sulfonylurea plus metformin) were randomised to receive bedtime insulin

H. Yki-Järvinen (FE) - M. Tükkainen Department of Medicine, University of Helsinki, P.O. Box 340. FIN-00029 HUCH, Helsinki, Fisland e-mail: vkiineviiiree helainki, fi Tel: +358-50-4271664 Fas: +358.9.47171896

R. Kauppinen-Mäkelin - K. Nikkilä Jorvi Hospital Espoo, Finland



Abstract Aims/hypothesis: In type 2 diabetic patients we glargine with metformin (G+MET) or bedtime NPH with compared 9 months of combination therapy with insulin metformin (NPH+MET) for 36 weeks. The patients were glargine and metformin with 9 months of NPH insulin combined with metformin. The primary focus was changes in modern to send the results of home glucose monitoring to HbA1e; secondary focus was diurnal glucose profiles and treatment centres. The goal was to achieve a fasting plasma glucose (FPG) of 4.0 to 5.5 mmol/l in both groups. Results: During the last 12 weeks, FPGs averaged 5.75± seven centres, 110 insulin-naive type 2 diabetic patients 0.02 and 5.96±0.03 mmol/l (p<0.001) and insulin doses were 68±5 and 70±6 IU/day (0.69±0.05 and 0.66±0.04 IU kg" day", NS) in the G+MET and NPH+MET groups. respectively. At 36 weeks, mean HbA1c was 7.14±0.12 and 7.16±0.14%, respectively (NS). Symptomatic, but not confirmed symptomatic, hypoglycaemia was significantly lower during the first 12 weeks in the G+MET group (4.1± 0.8 episodes/patient-year) than in the NPH+MET group (9.0±2.3 episodes/patient-year, p<0.05), but not significantly different thereafter. Glucose levels before dinner were higher in the NPH+MET group (10.1±0.3 mmol/l) than in the G+MET group (8.6±0.3 mmol/l, p=0.002) throughout the 36-week study. With regard to baseline characteristics such as initial glycaemia or C-peptide, there was no difference between patients who achieved good glycaemic control (HbAse <7.0%) and those who did not. Differences were seen in the following: between study centres, weight gain during the run-in period and insulin therapy, and FPG during the last 12 weeks (5.7±0.2 vs 6.7± 0.3 mmol/l for patients reaching vs those not reaching target, p=0.01). Conclusions/interpretation: Good glycsemic control can be achieved with both G+MET and NPH+ MET. Use of G+MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinnertime hyperglycaemia compared with NPH+MET.

> Keywords Glucose - Insulin analogues - Insulin therapy Metformin - Type 2 diabetes

Hannele Yki-Jarvinen

Yki-Jarvinen et al, Diabetologia 2006; 49: 442-451



Emerging Treatments and Technologies

The Treat-to-Target Trial

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MATTHEW C. RIDDLE, MD¹ JULIO ROSENSTOCK, MD² JOHN GERICH, MD³ ON BEHALF OF THE INSULIN GLABOINE 4002 STUDY INVESTIGATORS*

order of β-cell dysfunction. Patients using oral therapy for it seldom achieve and maintain the recommended 7% HbA₁₅ goal (1,2) for glycemic control and are exposed to increasing risks of diabetic complications as control worsens over time (3–5). The U.K. Prospective Diabetes Study (UKPDS) (6) showed that

ype 2 diabetes is a progressive dis-

OBJECTIVE — To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA_{1c}.

RESEARCH DESIGN AND METHODS

week multicenter trial, 756 overweight men and (HbA_{1x} >7.5%) on one or two oral agents continue glargine or NPH once daily, titrated using a simp glucose (FPG) ≤ 100 mg/dl (5.5 mmol/l). Outcome and percentage of patients reaching HbA_{1x} $\leq 7\%$ wi

RESULTS — Mean FPG at end point was similar [0.5 vs. 6.7 mmol/l]), as was HbA₁₁ (6.96 vs. 6.97 HbA₂₁₆ \leq 7% with each insulin type. However, near documented nocturnal hypoglycemia (\leq 72 mg/dI] P < 0.05). Moreover, rates of other categories of lower with glargine.

CONCLUSIONS — Systematically titrating bedi safely achieve 7% HbA_{1e} in a majority of overweigh between 7.5 and 10.0% on oral agents alone. In di nocturnal hypoglycemia than NPH, thus reducing simple regimen may facilitate earlier and effective i proving achievement of recommended standards of

Keep increasing the insulin to drive down the HbA1c

Diabetes Care 26:3080-3086, 2003 insulin simpler and more effective has been tested in several small studies (10-

n of longthile prior insulin is a defined



Julio RosenstockMatthew RiddleRiddle et al, Diabetes Care 2003; 26: 3080-3086

Espoo, Finland

Diabenologia (2006) 49: 442-451 DOI 10.1007/s00125.005-0132-0

ARTICLE

H. Yki-Järvinen · R. Kauppinen-Mäkelin · M. Tilikkainen · M. Vähätalo · H. Virtamo · K. Nikkilii · T. Tulokas · S. Hulme · K. Hardy · S. McNulty · J. Hänninen · H. Levänen · S. Lahdenperä · R. Lehtonen · L. Ryysy

Insulin glargine or NPH combined with metformin

in type 2 diabetes: the LANMET study

Received: 4 May 2005 / Accepted: 7 November 2005 / Published online: 3 February 2006 © Springer-Verlag 2006

Abstract Absu/hypothesis: In type 2 diabetic patients we compared 9 months of combination therapy with insulin metformin (NPH+MET) for 36 weeks. The patients were

their insulin dose and use a of home glucose monitoring to al was to achieve a fasting plasto 5.5 mmol/l in both groups weeks, FPGs averaged 5.75± (p<0.001) and insulin doses zy (0.69±0.05 and 0.66±0.04 IU MET and NPH+MET groups, mean HbA1c was 7.14±0.12 vely (NS). Symptomatic, but not hypoglycaemia was significantly eeks in the G+MET group (4.1± than in the NPH+MET group year, p<0.05), but not signifi-Glucose levels before dinner +MET group (10.1±0.3 mmol/l) sup (8.6±0.3 mmol/l, p=0.002) study. With regard to baseline

enancermuse such as initial glycaemia or C-peptide, there was no difference between patients who achieved good glycaemic control (HbA, i, <7.0%) and those who did not. Differences were seen in the following: between study centres, weight gain during the run-in period and insulin therapy, and PFG during the last 12 weeks (5.7±0.2 vs.6.7± 0.3 mmol/1 for patients reaching vs those not reaching target, p<0.01). Conclusions'interpretation: Good glycaemic control can be achieved with both G+MET and NPH+ MET. Use of G+MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinnertime hypoglycaemia compared with NPH+MET.

Keywords Glucose · Insulin analogues · Insulin therapy Metformin · Type 2 diabetes

Hannele Yki-Jarvinen

Yki-Jarvinen et al, Diabetologia 2006; 49: 442-451

Emerging Treatments and Technologies

The Treat-to-Target Trial

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MATTHEW C. RIDDLE, MD¹ JULIO ROSENSTOCK, MD² JOHN GERICH, MD³ ON BEHALF OF THE INSULIN GLABOINE 4002 STUDY INVESTIGATORS*

using oral therapy for it seldom achieve and maintain the recommended 7% HbA_{1c} goal (1,2) for glycemic control and are exposed to increasing risks of diabetic complications as control worsens abetic 3-5). The U.K. Prospective Diabetes Study (UKPDS) (6) showed that

ype 2 diabetes is a progressive dis-

order of β-cell dysfunction. Patients

OBJECTIVE — To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA_{1c}.

RESEARCH DESIGN AND METHODS

week multicenter trial, 756 overweight men and (HbA_{1c} >7.5%) on one or two oral agents continue glargine or NPH once daily, titrated using a simpl glucose (FPG) ≤ 100 mg/dl (5.5 mmod/). Outcome and percentage of patients reaching HbA_{1c} $\leq 7\%$ wi

RESULTS — Mean FPG at end point was similar [0.5 vs. 6.7 mmol/l]), as was HbA₁₁₂ (6.96 vs. 6.97) HbA₂₁₂ \leq 7% with each insulin type. However, near documented nocturnal hypoglycemia (\leq 72 mg/dI] $P \leq$ 0.05). Moreover, nutes of other categories of lower with glargine.

CONCLUSIONS — Systematically titrating bedi safely achieve 7% HbA_{1e} in a majority of overweigh between 7.5 and 10.0% on oral agents alone. In d nocturnal hypoglycemia than NPH, thus reducing simple regimen may facilitate earlier and effective is proving achievement of recommended standards of

Keep increasing the insulin to drive down the HbA1c But

their insulin dose and use a a of home glucose monitoring to al was to achieve a fasting plasto 5.5 mmol/l in both groups. weeks, FPGs averaged 5.75± 1/1 (p<0.001) and insulin doses zy (0.69±0.05 and 0.66±0.04 IU +MET and NPH+MET groups, mean HbA1c was 7.14±0.12 vely (NS). Symptomatic, but not hypoglycaemia was significantly veeks in the G+MET group (4.1± than in the NPH+MET group -year, p<0.05), but not signifi-Glucose levels before dinner +MET group (10.1±0.3 mmol/l) sup (8.6±0.3 mmol/l, p=0.002) study. With regard to baseline tial glycaemia or C-peptide, there en patients who achieved good <7.0%) and those who did not. the following: between study ng the run-in period and insulin he last 12 weeks (5.7±0.2 vs 6.7± reaching vs those not reaching onvinterpretation: Good plycaeed with both G+MET and NPH+

MET. Use of G+MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinnertime hyperglycaemia compared with NPH+MET.

Keywords Glucose · Insulin analogues · Insulin therapy Metformin · Type 2 diabetes



Julio RosenstockMatthew RiddleRiddle et al, Diabetes Care 2003; 26: 3080-3086

Hannele Yki-Jarvinen

Yki-Jarvinen et al, Diabetologia 2006; 49: 442-451

ARTICLE

Diabeteologia (2008) 49: 442-451 DOI:10.1007/s00125.005.0132.0

H. Yiki-Järvinen · R. Kauppinen-Mäkelin · M. Tilkkainen · M. Vähätalo · H. Virtamo · K. Nikkilä · T. Tulokas · S. Hulmo · K. Hardy · S. McNulty · J. Hänninen · H. Levänen · S. Lahdenperä · R. Lehtonen · L. Rysys)

Insulin glargine or NPH combined with metformin

in type 2 diabetes: the LANMET study

Received: 4 May 2005 / Accepted: 7 November 2005 / Published online: 3 February 2006 © Springer-Verlag 2006

Abstract Absu/hypothesis: In type 2 diabetic patients we compared 9 months of combination therapy with insulin metformin (NPH+MET) for 36 weeks. The patients were

Emerging Treatments and Technologies ORIGINAL ARTICLE

The Treat-to-Target Trial

and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA12

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MATTHEW C. RIDDLE, MD JULIO ROSENSTOCK, MD JOHN GERICH, MD

ON BEHALF OF THE INSULIN GLABOINE 4002 STUDY INVESTIGATORS*

using oral therapy for it seldom achieve and maintain the recommended 7% HbA1c goal (1,2) for glycemic control and are exposed to increasing risks of diabetic complications as control worsens **OBJECTIVE** — To compare the abilities and associated hypoglycemia risks of insulin glarging over time (3-5). The U.K. Prospective Di-

ype 2 diabetes is a progressive dis-

order of β-cell dysfunction. Patients

abetes Study (UKPDS) (6) showed that

Diabeteologia (2008) 49: 442-451 DOI:10.1007/s00125.005.0132.0

ARTICLE

H. Yki-Järvinen · R. Kauppinen-Mäkelin · M. Tiikkainen · M. Vähätalo · H. Virtamo · K. Nikkilä · T. Tulokas - S. Hulme - K. Hardy - S. McNulty -J. Hänninen · H. Levänen · S. Lahdenperä · R. Lehtonen - L. Ryysy

Insulin glargine or NPH combined with metformin

in type 2 diabetes: the LANMET study

Received: 4 May 2005 / Acceptol: 7 November 2005 / Published online: 3 February 2006 C Springer-Verlag 2006

Abstract Aims/hypothesis: In type 2 diabetic patients we glargine with metformin (G+MET) or bedtime NPH with compared 9 months of combination therapy with insulin metformin (NPH+MET) for 36 weeks. The patients were

RESEARCH DESIGN AND week multicenter trial, 756 (HbA1, >7.5%) on one or two glargine or NPH once daily, ti glucose (FPG) ≤100 mg/dl (5.5 and percentage of patients reach

RESULTS - Mean FPG at er [6.5 vs. 6.7 mmol/I]), as was Hh $HbA_{1c} \leq 7\%$ with each insulin t documented nocturnal hypogl P < 0.05). Moreover, rates of lower with glargine.

CONCLUSIONS - System safely achieve 7% HbA1c in a m between 7.5 and 10.0% on or nocturnal hypoglycemia than ? simple regimen may facilitate proving achievement of recon

Keep increasing the insulin to drive down the HbA1c But increasing the insulin increases

se and use a monitoring to a fasting plasn both groups iveraged 5.75± insulin doses 0.66±0.04 IU +MET groups was 7.14±0.12 matic, but no is significantly T group (4.1± H+MET group ut not signifibefore dinner 1±0.3 mmol/1 old, p=0.002) rd to baseline -peptide, there achieved good e who did not. between study iod and insulin 5.7±0.2 vs 6.7± e not reaching Good glycas-MET and NPHhypoglycaemia hyperglycaemia

sulin therapy

the weight

Matthew Riddle Julio Rosenstock

Hannele Yki-Jarvinen

Yki-Jarvinen et al, Diabetologia 2006; 49: 442-451


Riddle et al, Diabetes Care 2003; 26: 3080-3086

A patient in Dr Ryder's clinic who followed the treat to target approach

- May 2006
- Wt = 160 kg
- BMI = 53
- 325 units insulin daily with pioglitazone
- HbA1c = 6.7%



Roux-en-Y stomach gastric bypass surgery





- May 2006
- Wt = 160 kg
- BMI = 53
- Trouser size = 54 inch
- 325 units insulin daily with pioglitazone etc
- HbA1c = 6.7%
- BP 162/75 on 3-4 antihypertensive agents



- April 2008
- Wt = 83 kg
- BMI = 27
- Trouser size = 32 inch
- No insulin; no OHAs
- HbA1c = 7%
- BP 112/70 no anti-hypertensives



• May 2006

• April 2008





Spent 1 month in intensive care unit post op because of post op complications

- 325 units insulin daily with pioglitazone etc
- HbA1c = 6.7%
- BP 162/75 on 3-4 antihypertensive agents

- No insulin; no OHAs
- HbA1c = 7%
- BP 112/70 no anti-hypertensives







Wouldn't it be great if there was a less invasive procedure?

- 325 units insulin daily with pioglitazone etc
- HbA1c = 6.7%
- BP 162/75 on 3-4 antihypertensive agents

- No insulin; no OHAs
- HbA1c = 7%
- BP 112/70 no anti-hypertensives








Lisbon 2011


OP 31 Metabolic effect of bariatric surgery

Charlotte de Jonge

EndobarrierTM duodenal-jejunal bypass liner rapidly improves diabetes parameters paralleled by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients




Endobarrier – implantable duodenal-jejunal liner






Fluoropolymer Nitinol wall Anchor

60 cm impermeable sleeve Minimally invasive



Roux-en-Y gastric bypass surgery

Weight loss and diabetic improvement





Lisbon 2011

OP 31 Metabolic effect of bariatric surgery



EndobarrierTM duodenal-jejunal bypass liner rapidly improves diabetes parameters paralleled by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients

watch

Roma Ha 15 Sep 20 16:00 - 16:

92 viewer

:=

Outline

de Jonge, et al.

View Sessi

REVISE- Diabesity study came into existence during this presentation with its outline as notes "on the back of an envelope" completed before the presentation was finished!



EASD 2011

-

Q

2 year Endohance BCD hira audit feul wes jear Group 1 titrate live up to Img ar max bleated Group 2 Endo Sacrier Mowed by kelte sper + Sperne nes-11 + Lim Sky + Conh Ryder REJ – notes on proposed study made during EASD endobarrier presentation, 2011

2 year endobance ABCD hira audit Jaulus \checkmark BMI 35 / Merearch HAIC 8 / Became ≥7.5% Group 0 h'umal case". Group 1 titrate lira up to 3mg or max pleated Group 2 Endo Jarrier Mowed by Kelte sperce + Contres " + Lim Sky

2 year endobance ASO hira audit ! url an eseat Became 4 contributing centres rade A unal Group 1 titrate live up to 3mg ar max bleated Group 0 Mowed by kelte spera Endo James Group 2 Sal 10 152 + Lim Sky Cont

2 year endobance ABCD hira audit feul und 1Part Became 4 contributing centres Group o n'unal case". Became Dr Sen Gupta! Group 1 titrate lina up to Imp as max plead Endo Varier Mowed by kelf & sperce Group 2 Lira Sul-10 11 11 + Lim Sky + Conl

2 year endobance ABCD hira audit feul wes Became the endobarrier plus liraglutide 1.2mg group Group o n'unal case Group 1 titrate live up to 3mg or max bleated Group 2 Ende barrier Mowed by kelte sperce + Lim 3kg + Cont

2 year endohance ABCD hira audit failurs Became the endobarrier plus liraglutide 1.2mg group Group 0 n'undel case Group 1 titrate live up to 3mg or max bleated Group 2 Endo barrier Mowed by kelfe sperce Lira Ja 11 4 11 + Lim Jung + Con

2 year endohance phira audit f Became the endobarrier plus liraglutide 1.2mg group Group 0 n'unal case Group 1 titrate lira up 0 Group 2 Endo Jacrier Don Became the endobarrier instead of liraglutide group o to Imp as max pleated Became the liraglutide 1.8mg group Z 11 11 +

frudy ABGD pay for endobrances Nove polide, here X Gaytonenberdegasts we Collaboratos 1? - ale statistin

Concept & timelines for the trial

- EASD 2011
- 2012-3 grant, ethics, R&D approval
- July 2013 first patient treated
- April 2016 1-year complete for all patients
- March 2017 2-year results



To investigate the effects of adding proximal intestinal exclusion to GLP-1RA therapy not achieving targets, on weight and HbA1c compared to either treatment alone

Study design: Selection Criteria

INCLUSION CRITERIA:


- Type 2 diabetes
- Liraglutide treated for ≥ 6 months
- HbA1c ≥58mmol/mol (7.5%)
- Obesity, BMI ≥35kg/m²
- Stable weight, HbA1c (3 months)

EXCLUSION CRITERIA:

- Safety considerations:
- Bleeding risk: aspirin, warfarin
- Infection
- Pregnancy
- Conditions interfering with endobarrier placement/ findings


Study design:

Open label, multicentre, parallel group, randomised controlled trial



Study design:

Open label, multicentre, parallel group, randomised controlled trial





- 3-monthly visits: interview, anthropometry, blood tests (fbc, u&e, lft, amylase, lipids, HbA1c)
- Primary outcome: HbA1c at 2 years
- Subgroup MRI liver and pancreas baseline and 4 months


Results – Piya Sen Gupta

- Flowsheet of study subjects
- Baseline characteristics
- Efficacy:
- weight
- HbA1c and diabetes medications
- Cardiovascular risk
- Liver fat

Assessed for eligibility (n=195)








Baseline characteristics

Parameter	Endobarrier +liraglutide	Endobarrier	Liraglutide	
	N=24	N=24	N=22	
Age (years)	52.0±11.7	50.7±8.4	54.0±10.1	
Sex (% male)	41.7	29.2	36.4	
Ethnicity (% Caucasian)	66.7	70.8	72.7	
*Diabetes duration (yrs)	11.2 (6.7-17.1)	10.3 (7.8-12.7)	13.3 (9.0-18.4)	
Taking insulin (%)	58.3	25.0	45.5	
BMI (kg/m ²)	40.3±4.8	41.7±4.9	40.6±4.4	
Weight (kg)	112.8±20.4	115.6±19.4	113.9±14.9	
HbA1c (mmol/mol)	81.5±14.9	78.1±19.0	82.5±18.8	
HbA1c (%)	9.6±1.4	9.3±1.7	9.7±1.7	


**interquartile range*

No significant differences between groups


Impact of treatment on weight over 1 year




Impact of treatment on HbA1c over 1 year



% frequency of diabetes medications at baseline by treatment group



Number of new/ stopped diabetes medications started in each intervention group



Change in total daily dose of insulin by treatment group

E+L:
$$-76(-96 \text{ to } -15)$$

E: $-14(-20 \text{ to } 34)$
L: $-28(-49 \text{ to } 14)$


Impact of treatment on 10-year cardiovascular risk

10-Year CV risk score parameters	Q-risk2	UKPDS
Age, Sex, Ethnicity, Smoking status	\checkmark	\checkmark
Postcode	\checkmark	
Diabetes status	\checkmark	
Duration of diabetes, HbA1c		\checkmark
Hypertension status, Rheumatoid arthritis, CKD IV-V	\checkmark	
Atrial fibrillation	\checkmark	\checkmark
Cholesterol:HDL	\checkmark	\checkmark
Systolic BP	\checkmark	
Diastolic BP		\checkmark
BMI	\checkmark	

Q-risk2 at baseline

- 38.7% intermediate (10-20%) risk
- 40.0% high (>20%) risk


Impact of treatment on 10-year cardiovascular risk




-25

Liver fat pre- and post-MR images

Pre-endobarrier









Liver fat pre- and post-MR images

Pre-endobarrier





4-months later

Liver fat – n8

Mean hepatic fat fraction fell from 15.9±9.4% to 2.9±4.5% post-endobarrier (87.5±25.2% reduction), P=0.0026

Pancreatic fat – n8

Mean pancreatic fat fraction fell from 6.9% to 1.3% post-endobarrier, P=0.02

Safety and tolerability – Barbara McGowan

- Serious adverse events
- Quality of life
- Satisfaction scores

Safety Data


Table of Serious Adverse Events (related)

	Early removal ✓ or X	Endobarrier +liraglutide	Endobarrier	Liraglutide
Gastrointestinal symptoms	\checkmark	3	2	
Symptomatic cholelithiasis	\checkmark		2	
GI Bleed	\checkmark		1	
Obstruction	\checkmark	1	1	
Complicated removal	n/a		1	
Liver abscess	X		2	


5/48 (10.4%) cases had serious complications and all had a full recovery following endobarrier removal

Liver abscess - case 1

- 51yr Caucasian female
- Base BMI 53.9kg/m², HbA1c 73mmol/mol (8.8%)
- 01/07/2014 Endobarrier implant
- 6 weeks later admitted to a local hospital while on holiday with nausea, vomiting, fevers and abdominal pain
- → Glasgow CT abdomen:



After 10 weeks antibiotics



- Attempted US-guided drainage was unsuccessful
- IV Tazocin 12 days, PO ciprofloxacin 16 weeks as she refused removal
- At 1-year Endobarrier removed weight loss 18.9kg, HbA1c +0.9%

Liver abscess – case 2


- 48yr Afrocaribbean male
- Base BMI 44.3kg/m², HbA1c 67mmol/mol (8.3%)
- 30/09/2013 Endobarrier implant
- At 1-year DNA'd planned removal, seen at 14 months
- 10 days later Admitted with septic shock, hyperosmolar hyperglycaemic state glucose 47.4mmol/l, Ur42, Cr348, bili 28, ALT100, AIP140, CRP 239
- 10/12/2014 CT abdomen 13x10x12cm right lobe hepatic abscess
- Abscess drained twice 500mls pus removed and IV then PO antibiotics
- Abscess improved
- Feb 2015 Endobarrier removal

Liver abscesses

- FDA pivotal trial in USA ENDO trial
- Design: RCT double blind, sham control, 500 patients, 25 centres
- July 2015, ENDO trial was terminated early (325/500 enrolled) due to 7 /217 (3.2%) cases of hepatic abscess (exceeded safety threshold 2%)
- Liver abscesses occurred 40-424 days after implant
- 3000 cases worldwide since 2009 liver abscess rate ~ 0.73%
- Recommendations under consideration:
- Antibiotic cover for implant and explant procedures
- Shortened implant period (9 months)


EQ-5D quality of life – health state at 1-year

"Indicate how good or bad your health state is today in your opinion (the best state you can imagine is marked 100, the worst state you can imagine is marked 0.)"



Patient satisfaction – NHS friends and family test

"How likely would you be to recommend the treatment you have had in this research study to family and friends based on your experience?"



Summary

- In E+L group HbA1c fell by 22.8 mmol/mol (2.1%) from 81.5 (9.6%) to 58.7 mmol/mol (7.5%) and weight fell by 12.4 kg from 112.8kg to 100.4 kg
- Both endobarrier groups produced reduction in weight with a reduction in liver and pancreatic fat
- E+L group demonstrated a trend towards superiority with HbA1c reduction at 1-year, achieved with:
 - reduction in other diabetes medications
 - reduction in 10-year cardiovascular risk
- Safety profile is reasonable ongoing clinical vigilance during the implant period is advised
- Patient satisfaction levels are high

Conclusion

These data suggest that adding proximal intestinal exclusion in patients with suboptimally performing GLP1-RA therapy rather than switching to it or increasing GLP-1RA dose, has a useful role in the management of refractory diabetes and obesity.

Acknowledgements

All study participants

Endoscopy team: Mark Anderson, Louise Bensaid, Ross Carter, Ed Fogden, David Galloway, Bu Hayee, Lesley Sadler

Research Nurses/ CRF facility: Alison Begg, Elka Giemza, Manju Joy, Fiona Kinney, Fran Lloyd, Hilary Peddie, Andrew Pernet, Bula Wilson, Louisa Green, Noah Yogo

Fellows: Ramdeep Bajwa, Chris Kueh, Siang Lee, Sebastian Lugg, Laura McCreight, Lois Murray

Administration: Melissa Cull, Rosa DaCosta, Vikram Johal, Ben Stothard, Melanie Wyres

R&D: Jocelyn Bell, Sinead Collinge

Statistician: Andrew Blann

Data monitoring committee: Cliff Bailey, John McClure, Parth Narendran

Association of British Clinical Diabetologists

NIHR/ Wellcome Trust King's Clinical Research Facility